Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.
- Status
- WITHDRAWN
- Phase
- PHASE2
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
- Status
- RECRUITING
- Phase
- PHASE2
Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- WITHDRAWN
- Phase
- PHASE1
Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Status
- RECRUITING
- Phase
- PHASE3
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
- Status
- RECRUITING
- Phase
- PHASE2
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
- Status
- SUSPENDED
- Phase
- PHASE1
Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies
- Status
- RECRUITING
- Phase
- PHASE3
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- Status
- RECRUITING
- Phase
- PHASE3
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
- Status
- RECRUITING
- Phase
- PHASE2